RxDoctor Payments Data

Conner Overfelt

Physician Assistant · Salem, VANPI 1417580572

Payments from drug & device makers

$8,735in general payments, 2019–2025

Across 433 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boston Scientific$966
  • AstraZeneca$964
  • E.r. Squibb & Sons, L.L.C.$828
  • Johnson & Johnson$605
  • Amgen$557
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$8,59498%
  • Education$1412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,735 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$72,201
Medicare patients
934
Services billed
1,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$275,096
EntrestoSacubitril/Valsartan49$69,401
XareltoRivaroxaban41$55,292
FarxigaDapagliflozin Propanediol29$27,321
Metoprolol Succinate383$4,108
Ranolazine ErRanolazine18$2,427
Atorvastatin Calcium209$2,109
Midodrine Hcl26$1,790
Isosorbide Mononitrate ErIsosorbide Mononitrate130$1,311
Lisinopril163$1,307
Potassium Chloride54$1,229
Losartan Potassium157$1,153
Metoprolol Tartrate170$1,129
Carvedilol141$1,015
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$275,096242 claims
NovartisEntresto$1,404$69,40149 claims
Johnson & JohnsonXarelto$605$55,29241 claims
AstraZenecaFarxiga$964$27,32129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →